Nykode Therapeutics - Grant of share options
Nykode Therapeutics ASA (NYKD) · publisert 1. juli 2024 kl. 20:20 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass |
|---|---|---|---|---|---|---|---|
| Michael Engsig | CEO | Annet Tildeling | 494 749 | 0 NOK | 1. juli 2024 | NO0010714785 | Outside of trading venue |
| Harald Gurvin | CFO | Annet Tildeling | 183 304 | 0 NOK | 1. juli 2024 | NO0010714785 | Outside of trading venue |
| Agnete B. Fredriksen | Chief Scientific Officer & Business Development | Annet Tildeling | 177 515 | 0 NOK | 1. juli 2024 | NO0010714785 | Outside of trading venue |
| Klaus Edvardsen | Chief Research & Development Officer | Annet Tildeling | 212 927 | 0 NOK | 1. juli 2024 | NO0010714785 | Outside of trading venue |
| Louise Stubbe | Chief Legal Officer | Annet Tildeling | 163 965 | 0 NOK | 1. juli 2024 | NO0010714785 | Outside of trading venue |
Vedlegg
- Attachment 240701.pdf (application/pdf, originaldokument)
Meldingstekst
Oslo, Norway, July 1, 2024 - A total of 3,159,019 share options have been granted to employees of Nykode Therapeutics ASA under the company’s share option scheme, of which 1,232,460 share options have been granted to primary insiders. The share options will have a strike price of NOK 15.35 per share, have a five-year term and will vest equally over a four-year vesting period.
Please see further details in attached document.